Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 4/2016

16.09.2016

Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers

verfasst von: Christoph Langenstein, Diana Schork, Klaus Badenhoop, Eva Herrmann

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Problem: Graves’ disease (GD) is an important and prevalent thyroid autoimmune disorder. Standard therapy for GD consists of antithyroid drugs (ATD) with treatment periods of around 12 months but relapse is frequent. Since predictors for relapse are difficult to identify the individual decision making for optimal treatment is often arbitrary. Methods: After reviewing the literature on this topic we summarize important factors involved in GD and with respect to their potential for relapse prediction from markers before and after treatment. This information was used to design a mathematical model integrating thyroid hormone parameters, thyroid size, antibody titers and a complex algorithm encompassing genetic predisposition, environmental exposures and current immune activity in order to arrive at a prognostic index for relapse risk after treatment. Conclusion: In the search for a tool to analyze and predict relapse in GD mathematical modeling is a promising approach. In analogy to mathematical modeling approaches in other diseases such as viral infections, we developed a differential equation model on the basis of published clinical trials in patients with GD. Although our model needs further evaluation to be applicable in a clinical context, it provides a perspective for an important contribution to a final statistical prediction model.
Fußnoten
1
„Empirical models are based on direct observation, measurement and extensive data records. Mechanistic models are based on an understanding of the behavior of a system’s components. For example, you can observe the change of the tides over many years, and construct an empirical model that allows you to predict when tides will occur, with no understanding of how the earth, moon and sun interact. You can also create a mathematical, mechanistic model that uses the laws of physics to predict tides.” [78]
 
Literatur
2.
Zurück zum Zitat Badenhoop K, Donner H, Braun J, Siegmund T, Rau H, Usadel KH. Genetic markers in diagnosis and prediction of relapse in Graves’ disease. Exp Clin Endocrinol Diabetes. 1996;104(Suppl):98–100.CrossRefPubMed Badenhoop K, Donner H, Braun J, Siegmund T, Rau H, Usadel KH. Genetic markers in diagnosis and prediction of relapse in Graves’ disease. Exp Clin Endocrinol Diabetes. 1996;104(Suppl):98–100.CrossRefPubMed
3.
Zurück zum Zitat Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817–9.CrossRefPubMedPubMedCentral Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817–9.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol. 2014. doi:10.1111/cen.12688. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol. 2014. doi:10.​1111/​cen.​12688.
6.
Zurück zum Zitat Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.CrossRefPubMed Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.CrossRefPubMed
7.
Zurück zum Zitat Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves’ disease relapse. Clin Endocrinol. 2005;63:657–62.CrossRef Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, et al. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves’ disease relapse. Clin Endocrinol. 2005;63:657–62.CrossRef
9.
Zurück zum Zitat Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–4.PubMed Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–4.PubMed
10.
Zurück zum Zitat Ringold D. A, Nicoloff JT, Kesler M, Davis H, Hamilton a, Mack T: further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid. 2002;12:647–53.CrossRefPubMed Ringold D. A, Nicoloff JT, Kesler M, Davis H, Hamilton a, Mack T: further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid. 2002;12:647–53.CrossRefPubMed
11.
Zurück zum Zitat Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82–90.CrossRefPubMedPubMedCentral Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82–90.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123:183.e1–9.CrossRef Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123:183.e1–9.CrossRef
13.
Zurück zum Zitat Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease. Thyroid. 2002;12:849–53.CrossRefPubMed Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease. Thyroid. 2002;12:849–53.CrossRefPubMed
14.
Zurück zum Zitat Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves’ disease. Thyroid. 2007;17:767–72.CrossRefPubMed Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves’ disease. Thyroid. 2007;17:767–72.CrossRefPubMed
15.
Zurück zum Zitat Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immnunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254–7.PubMed Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immnunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254–7.PubMed
16.
Zurück zum Zitat Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases. Neuroimmunomodulation. 2006;13:309–17.CrossRefPubMed Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases. Neuroimmunomodulation. 2006;13:309–17.CrossRefPubMed
17.
Zurück zum Zitat Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015;7:2485–98.CrossRefPubMedPubMedCentral Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients. 2015;7:2485–98.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves’ disease and the vitamin D status in a polish population study. Exp Clin Endocrinol Diabetes. 2006;114:329–35.CrossRefPubMed Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves’ disease and the vitamin D status in a polish population study. Exp Clin Endocrinol Diabetes. 2006;114:329–35.CrossRefPubMed
19.
Zurück zum Zitat Corapcioglu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002;12:613–7.CrossRefPubMed Corapcioglu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002;12:613–7.CrossRefPubMed
20.
Zurück zum Zitat Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and helicobacter pylori: the correlation is present only in Graves’s disease. World J Gastroenterol. 2012;18:1093–7.CrossRefPubMedPubMedCentral Bassi V, Marino G, Iengo A, Fattoruso O, Santinelli C. Autoimmune thyroid diseases and helicobacter pylori: the correlation is present only in Graves’s disease. World J Gastroenterol. 2012;18:1093–7.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563–72.CrossRefPubMed Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563–72.CrossRefPubMed
22.
Zurück zum Zitat Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788–830.PubMed Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788–830.PubMed
23.
Zurück zum Zitat Aleksić A, Aleksić Z, Stojanović M. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves’ disease patients. Hell J Nucl Med. 2009;12:146–50.PubMed Aleksić A, Aleksić Z, Stojanović M. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves’ disease patients. Hell J Nucl Med. 2009;12:146–50.PubMed
24.
Zurück zum Zitat Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–80.CrossRefPubMed Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–80.CrossRefPubMed
25.
Zurück zum Zitat Yu H, Farahani P. Thyroid stimulating hormone suppression post-therapy in patients with Graves’ disease: a systematic review of pathophysiology and clinical data. Clin Invest Med. 2015;38:E31–44.CrossRefPubMed Yu H, Farahani P. Thyroid stimulating hormone suppression post-therapy in patients with Graves’ disease: a systematic review of pathophysiology and clinical data. Clin Invest Med. 2015;38:E31–44.CrossRefPubMed
26.
Zurück zum Zitat Neumann S, Place RF, Krieger CC, Gershengorn MC. Future prospects for the treatment of Graves’ hyperthyroidism and eye disease. Horm Metab Res. 2015;47:789–96.CrossRefPubMed Neumann S, Place RF, Krieger CC, Gershengorn MC. Future prospects for the treatment of Graves’ hyperthyroidism and eye disease. Horm Metab Res. 2015;47:789–96.CrossRefPubMed
27.
Zurück zum Zitat Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Investig. 2014;37:1041–8.CrossRef Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Investig. 2014;37:1041–8.CrossRef
28.
Zurück zum Zitat Wilson R, McKillop JH, Pearson C. Burnett a K, Thomson J a: differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol. 1988;73:312–5.PubMedPubMedCentral Wilson R, McKillop JH, Pearson C. Burnett a K, Thomson J a: differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol. 1988;73:312–5.PubMedPubMedCentral
29.
Zurück zum Zitat Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001;7:451–60.CrossRefPubMed Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001;7:451–60.CrossRefPubMed
30.
Zurück zum Zitat Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294:102–10.CrossRefPubMed Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294:102–10.CrossRefPubMed
31.
Zurück zum Zitat Sopori M. 21 review: effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372–7.CrossRefPubMed Sopori M. 21 review: effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372–7.CrossRefPubMed
32.
Zurück zum Zitat Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol. 2002;146:153–61.CrossRefPubMed Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol. 2002;146:153–61.CrossRefPubMed
33.
Zurück zum Zitat Mohlin E, Filipsson Nyström H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014;170:419–27.CrossRefPubMed Mohlin E, Filipsson Nyström H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010. Eur J Endocrinol. 2014;170:419–27.CrossRefPubMed
34.
35.
Zurück zum Zitat Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohn’s Colitis. 2014;8:717–25.CrossRef Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohn’s Colitis. 2014;8:717–25.CrossRef
36.
Zurück zum Zitat Guerra LN, Ríos De Molina MDC, Miler EA, Moiguer S, Karner M, Burdman JA. Antioxidants and methimazole in the treatment of Graves’ disease: effect on urinary malondialdehyde levels. Clin Chim Acta. 2005;352:115–20.CrossRefPubMed Guerra LN, Ríos De Molina MDC, Miler EA, Moiguer S, Karner M, Burdman JA. Antioxidants and methimazole in the treatment of Graves’ disease: effect on urinary malondialdehyde levels. Clin Chim Acta. 2005;352:115–20.CrossRefPubMed
37.
Zurück zum Zitat Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78:155–64.CrossRef Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78:155–64.CrossRef
38.
Zurück zum Zitat Laurberg P, Jørgensen T, Perrild H, Ovesen L, Knudsen N, Pedersen IB, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–28.CrossRefPubMed Laurberg P, Jørgensen T, Perrild H, Ovesen L, Knudsen N, Pedersen IB, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–28.CrossRefPubMed
39.
Zurück zum Zitat Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;10:1–10. Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;10:1–10.
40.
Zurück zum Zitat Dauksiene D, Dauksa A, Mickuviene N. Independent pretreatment predictors of Graves’ disease outcome. Med. 2013;49:427–34. Dauksiene D, Dauksa A, Mickuviene N. Independent pretreatment predictors of Graves’ disease outcome. Med. 2013;49:427–34.
41.
Zurück zum Zitat Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab. 1996;81:2986–93.PubMed Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid study group. J Clin Endocrinol Metab. 1996;81:2986–93.PubMed
42.
Zurück zum Zitat Wang P-W, Chen I-Y, Juo S-HH, Hsi E, Liu R-T, Hsieh C-J. Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J. 2013;1:251–8.PubMed Wang P-W, Chen I-Y, Juo S-HH, Hsi E, Liu R-T, Hsieh C-J. Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J. 2013;1:251–8.PubMed
43.
Zurück zum Zitat Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol. 2007;67:607–12. Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol. 2007;67:607–12.
44.
Zurück zum Zitat Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol. 1989;120:689–701.PubMed Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol. 1989;120:689–701.PubMed
45.
Zurück zum Zitat Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs. Thyroid. 1998;8:119–24.CrossRefPubMed Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs. Thyroid. 1998;8:119–24.CrossRefPubMed
46.
Zurück zum Zitat Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119–28.CrossRefPubMed Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119–28.CrossRefPubMed
47.
Zurück zum Zitat Morshed SA, Davies TF. Graves’ disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res. 2015;47:727–34.CrossRefPubMedPubMedCentral Morshed SA, Davies TF. Graves’ disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res. 2015;47:727–34.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Davies TF, Ando T, Lin R-Y, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115:1972–83.CrossRefPubMedPubMedCentral Davies TF, Ando T, Lin R-Y, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115:1972–83.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, et al.: A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves ’ Disease 2014;564–567. Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, et al.: A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves ’ Disease 2014;564–567.
51.
Zurück zum Zitat Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine. 2013;44:448–53.CrossRefPubMed Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine. 2013;44:448–53.CrossRefPubMed
52.
Zurück zum Zitat Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:1. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:1.
53.
Zurück zum Zitat Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves’ disease--prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50:127–32.CrossRef Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves’ disease--prospective randomized assessment of long-term treatment. Clin Endocrinol. 1999;50:127–32.CrossRef
54.
Zurück zum Zitat Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European multicentre trial Group of the Treatment of hyperthyroidism with antithyroid drugs. Clin Endocrinol. 1998;49:451–7.CrossRef Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European multicentre trial Group of the Treatment of hyperthyroidism with antithyroid drugs. Clin Endocrinol. 1998;49:451–7.CrossRef
55.
Zurück zum Zitat Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European multicenter study group on antithyroid drug treatment. J Clin Endocrinol Metab. 1993;76:1516–21.PubMed Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European multicenter study group on antithyroid drug treatment. J Clin Endocrinol Metab. 1993;76:1516–21.PubMed
56.
Zurück zum Zitat Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453–61.CrossRefPubMed Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 2007;40:453–61.CrossRefPubMed
57.
Zurück zum Zitat Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves’ disease. Endocrine. 2015;48:254–63.CrossRefPubMed Vita R, Lapa D, Trimarchi F, Benvenga S. Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves’ disease. Endocrine. 2015;48:254–63.CrossRefPubMed
58.
Zurück zum Zitat Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity. Thyroid. 2004;14:1047–55.CrossRefPubMed Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity. Thyroid. 2004;14:1047–55.CrossRefPubMed
59.
60.
Zurück zum Zitat Vita R, Lapa D, Vita G, Trimarchi F, Benvenga S. A patient with stress-related onset and exacerbations of Graves disease. Nat Clin Pract Endocrinol Metab. 2009;5:55–61.CrossRefPubMed Vita R, Lapa D, Vita G, Trimarchi F, Benvenga S. A patient with stress-related onset and exacerbations of Graves disease. Nat Clin Pract Endocrinol Metab. 2009;5:55–61.CrossRefPubMed
61.
Zurück zum Zitat Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93:3985–8.CrossRefPubMed Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93:3985–8.CrossRefPubMed
62.
Zurück zum Zitat Smye SW, Clayton RH. Mathematical modelling for the new millenium: medicine by numbers. Med Eng Phys. 2002;24:565–74.CrossRefPubMed Smye SW, Clayton RH. Mathematical modelling for the new millenium: medicine by numbers. Med Eng Phys. 2002;24:565–74.CrossRefPubMed
64.
Zurück zum Zitat Danziger, Elmergreen. Mathematical Theory of Periodic Relapsing Catatonia. Bull Math Biophys. 1954;16:15–21.CrossRef Danziger, Elmergreen. Mathematical Theory of Periodic Relapsing Catatonia. Bull Math Biophys. 1954;16:15–21.CrossRef
65.
Zurück zum Zitat Danziger, Elmergreen. The thyroid-pituitary homeostatic mechanism. Bull Math Biophys. 1956;18:1–13.CrossRef Danziger, Elmergreen. The thyroid-pituitary homeostatic mechanism. Bull Math Biophys. 1956;18:1–13.CrossRef
66.
Zurück zum Zitat Rashevsky N. Mathematical theory of biological periodicities: formulation of the n-body case. Bull Math Biophys. 1968;30:735–49.CrossRefPubMed Rashevsky N. Mathematical theory of biological periodicities: formulation of the n-body case. Bull Math Biophys. 1968;30:735–49.CrossRefPubMed
67.
Zurück zum Zitat Norwich K, Raymond R. Homeostatic control of the thyroxin concentration expressed by a set of linear differential equations. Bull Math Biophys. 1965;27:133–44.CrossRefPubMed Norwich K, Raymond R. Homeostatic control of the thyroxin concentration expressed by a set of linear differential equations. Bull Math Biophys. 1965;27:133–44.CrossRefPubMed
68.
Zurück zum Zitat DiStefano J, Stear E. Neuroendocrine control of thyroid secretion in living systems: a feedback control system model. Bull Math Biophys. 1968;30:8–26. DiStefano J, Stear E. Neuroendocrine control of thyroid secretion in living systems: a feedback control system model. Bull Math Biophys. 1968;30:8–26.
69.
Zurück zum Zitat Hatakeyama T, Yagi H. Computer simulation for hormones related to primary Thyropathy. Biol Cybern. 1985;52:259–66.CrossRefPubMed Hatakeyama T, Yagi H. Computer simulation for hormones related to primary Thyropathy. Biol Cybern. 1985;52:259–66.CrossRefPubMed
70.
Zurück zum Zitat Liu Y, Liu B, Xie J, Liu YX. A new mathematical model of hypothalamo-pituitary-thyroid axis. Math Comput Model. 1994;19:81–90.CrossRef Liu Y, Liu B, Xie J, Liu YX. A new mathematical model of hypothalamo-pituitary-thyroid axis. Math Comput Model. 1994;19:81–90.CrossRef
71.
Zurück zum Zitat Degon M, Chipkin SR, Hollot CV, Zoeller RT, Chait Y. A computational model of the human thyroid. Math Biosci. 2008;212:22–53.CrossRefPubMed Degon M, Chipkin SR, Hollot CV, Zoeller RT, Chait Y. A computational model of the human thyroid. Math Biosci. 2008;212:22–53.CrossRefPubMed
72.
Zurück zum Zitat Hoermann R, Eckl W, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. Eur J Endocrinol. 2010;162:1123–9.CrossRefPubMed Hoermann R, Eckl W, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. Eur J Endocrinol. 2010;162:1123–9.CrossRefPubMed
73.
Zurück zum Zitat Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto’s) thyroiditis. Math Med Biol. 2014;31:226–58.CrossRefPubMed Pandiyan B, Merrill SJ, Benvenga S. A patient-specific model of the negative-feedback control of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto’s) thyroiditis. Math Med Biol. 2014;31:226–58.CrossRefPubMed
74.
Zurück zum Zitat Silver N, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Brain. 1997;120:1149–61.CrossRefPubMed Silver N, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Brain. 1997;120:1149–61.CrossRefPubMed
75.
Zurück zum Zitat Velez de Mendizabal N, Hutmacher MM, Troconiz IF, Goni J, Villoslada P, Bagnato F, et al. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. PLoS One. 2013;8. doi:10.1371/journal.pone.0073361. Velez de Mendizabal N, Hutmacher MM, Troconiz IF, Goni J, Villoslada P, Bagnato F, et al. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach. PLoS One. 2013;8. doi:10.​1371/​journal.​pone.​0073361.
76.
Zurück zum Zitat Goede SL. Leow MK-SS, Smit JWA, Klein HH, Dietrich JW: hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull Math Biol. 2014;76:1270–87.CrossRefPubMed Goede SL. Leow MK-SS, Smit JWA, Klein HH, Dietrich JW: hypothalamus-pituitary-thyroid feedback control: implications of mathematical modeling and consequences for thyrotropin (TSH) and free thyroxine (FT4) reference ranges. Bull Math Biol. 2014;76:1270–87.CrossRefPubMed
77.
Zurück zum Zitat Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol. 2013;78:768–76.CrossRef Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol. 2013;78:768–76.CrossRef
Metadaten
Titel
Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers
verfasst von
Christoph Langenstein
Diana Schork
Klaus Badenhoop
Eva Herrmann
Publikationsdatum
16.09.2016
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 4/2016
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9386-8

Weitere Artikel der Ausgabe 4/2016

Reviews in Endocrine and Metabolic Disorders 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.